Completed PHASE2 INTERVENTIONAL 1-arm NCT00744900

Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC) (GFPC 07-01)

A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).

Sponsor: University Hospital, Brest

Conditions Lung Cancer

Interventions Pemetrexed, cisplatin

Updated 6 times since 2017 Last updated: Jul 24, 2009 Started: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Cancer and is currently completed. University Hospital, Brest leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Brest

Data source: University Hospital, Brest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aix-en-Provence, France , Angers, France , Antibes, France , Brest, France , Caen, France , Cergy-Pontoise, France , Charleville, France , Créteil, France , Draguignan, France , Gap, France and 14 more locations